Plain-English translation of NCT05647109 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study is testing two hormone medications—medroxyprogesterone acetate (MPA) or megestrol acetate (MA)—to treat early-stage endometrial cancer and precancerous changes in the uterus. Researchers want to understand which patients will respond well to this medication, and they're using special tissue analysis to predict treatment success before you start taking the medication.
Not all patients respond the same way to hormone treatment for early uterine cancer. By identifying which patients are likely to benefit from this medication before or during treatment, doctors hope to avoid unnecessary surgery and help patients keep their uterus if they want to.
You likely qualify if…
You likely don't qualify if…
You will take a daily hormone pill by mouth for as long as needed. Every 3 months, you'll have a hysteroscopy (a camera exam of your uterus) to check how your tissue is responding to the medication. During each exam, doctors will collect a small tissue sample to analyze in the laboratory. Your doctor will decide whether to continue, adjust, or stop the medication based on how your tissue changes over time. If your cancer progresses despite medication, your doctor may recommend surgery to remove your uterus.
AI-generated summary from trial data · Jun 10, 2026 · Not medical advice
China
Sponsor
Peking University People's Hospital
Collaborators
Peking University, Beihang University
Enrollment target
~244 participants
Started
September 2021
Primary completion
August 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
17 Years – 45 Years
Sex
Female only
Last updated on clinicaltrials.gov in May 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
WANG JIANLIU, PhD/MD
Peking University People's Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.